Latest News

A serious discussion about reforming Australia's use of health technology assessment should start with patient rights and the imposition of new obligations on advisory committees and decision-makers. The signs of institutional capture and the dangers of concessions as the price for participation. Once again, pharmacy sets the standard for advocacy with its consistent argument that out-of-pocket patient costs must be lowered.

Members of the Pharmaceutical Society of Australia have voted to support the constitutional changes necessary to acquire the Australasian College of Pharmacy.

AstraZeneca has maintained its lead in this year's Rare Cancers Australia Kosi Challenge 'Pharma Cup', with teams still building and just three weeks to go.

A $7.5 million philanthropic donation from Dennis Bastas, the CEO of DGB Health, will establish a new Health Leadership Academy at the University of Melbourne.

Specialised Therapeutics CEO Carlo Montagner said the approval was a meaningful milestone, but the company would not stop until it achieved reimbursement through the PBS.

Australia exports around $1.7 billion in pharmaceutical products to the US, around 40 per cent of the total. Blood products dominate Australia's pharmaceutical exports to the US.

What is the point of biosimilars and the promise of lower prices if the only beneficiary is the government's economic interest? Oh wait. The government's economic interest is the only consideration in Australia's HTA system.

Australian pharmaceutical manufacturing company IDT Australia has reported an 83 per cent increase in revenue for the first half of the financial year 2025.

The company recently announced the introduction of same-day pharmacy delivery in Sydney through its Leafio brand and a newly formed strategic distribution partnership with one of Australia’s biggest pharmacy networks.

The Generic and Biosimilar Medicines Association says that several policies to promote the use of biosimilars could deliver savings of $1.5 billion over the next five years.

The US FDA has granted fast-track designation for Neuren's NNZ-2591 for the treatment of Pitt Hopkins syndrome. 

CEO Gary Phillips said, "These new findings significantly enhance our understanding of scarring and the impact of topical pan-LOX inhibitors."